Claim Ledger
92% answered
Did management answer the analysts?
12 analyst questions audited.
View Claim Ledger →Anupam Rasayan India Limited — Q4 FY26
Anupam Rasayan reported a strong FY26 with consolidated revenue of ₹2,384 crore (+65% YoY) and EBITDA of ₹543 crore (+32% YoY), driven by robust execution across agrochemicals, pharma, and performance materials.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Anupam Rasayan reported a strong FY26 with consolidated revenue of ₹2,384 crore (+65% YoY) and EBITDA of ₹543 crore (+32% YoY), driven by robust execution across agrochemicals, pharma, and performance materials. The company's diversification strategy reduced agro dependence from 76% in FY22 to 55% in FY26. Operating cash flow improved to ₹334 crore on better working capital management. Management guided for 20-30% standalone revenue growth over 3-5 years, supported by a ₹14,000 crore order book. Key strategic moves include the acquisition of JHawk Fine Chemicals (US) and a definitive agreement to acquire 43.3-48.5% of Bliss GVS Pharma, creating a full pharma platform. No major capex is planned beyond maintenance. Risk: Integration of multiple acquisitions may strain management bandwidth and execution.
अनुपम रसायन ने वित्त वर्ष 2026 में शानदार प्रदर्शन किया। कंपनी की कुल कमाई ₹2,384 करोड़ रही, जो पिछले साल से 65% ज़्यादा है। कमाई में से मुनाफा (EBITDA) ₹543 करोड़ रहा, जो 32% बढ़ा। यह वृद्धि खेती की दवाओं, दवा उद्योग और परफॉरमेंस मटेरियल की मज़बूत बिक्री से हुई। कंपनी ने अपना कारोबार फैलाया है, जिससे खेती की दवाओं पर निर्भरता 76% (2022) से घटकर 55% (2026) रह गई। कंपनी के पास ₹14,000 करोड़ के ऑर्डर हैं और अगले 3-5 सालों में 20-30% सालाना वृद्धि का लक्ष्य है। उन्होंने अमेरिका की JHawk कंपनी खरीदी और Bliss GVS Pharma में हिस्सेदारी लेने का समझौता किया है। आगे बड़ा खर्च नहीं है। जोखिम: कई कंपनियों को एक साथ जोड़ने से प्रबंधन पर दबाव बढ़ सकता है।
Promises1 met · 0 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
1 promise
Promise Tracker
1 delivered, 0 close, 0 missed.
View Promises →
Risks
4 risks
Risk Intelligence
Integration risk from multiple acquisitions
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Order Book
₹14,000 crore
N/A
Total order book provides visibility for future revenue; management expects ~₹1,800-2,200 crore annual conversion.
Pharma Revenue Contribution (Standalone)
20%
+18pp YoY
Pharma segment grew from ~2% in FY22 to 20% in FY26, reflecting successful diversification.
High Performance Materials Revenue (Standalone)
₹305 crore
+214% vs FY22
Revenue from high performance materials tripled from ₹97 crore in FY22 to ₹305 crore in FY26.
Bliss GVS Pharma Capacity Utilization
30%
N/A
Current utilization low; management targets 60-70% in near to medium term, driving revenue growth.
What Changed vs Last Quarter
NEW
Standalone revenue growth of 20-30% CAGR over 3-5 years
Management expects standalone business to grow at 20-30% annually, driven by order book conversion and new molecule commercialization.
NEW
No major capex in near future; maintenance capex of ₹50-75 crore
All plants are commercialized; current capacity sufficient for near-term growth. Only maintenance and efficiency capex planned.
NEW
Bliss GVS Pharma capacity utilization to reach 60-70% in near to medium term
Management plans to increase Bliss's capacity utilization from 30% to 60-70%, leveraging Anupam's customer relationships and expertise.
NEW
Effective tax rate on standalone basis to be ~25% going forward
Management guided for a lower tax rate of around 25% on standalone operations.
DROPPED
Working capital days target below 200 by FY27
Management targets reducing working capital days from ~250 to below 200 by FY27, with near-term goal of ~220 days.
DROPPED
J-Hawk acquisition to be EPS-accretive from day one
The acquisition of J-Hawk Pine Chemicals is expected to be earnings accretive immediately upon consolidation, expected in Q4 FY26.
DROPPED
Growth momentum to continue into next fiscal year
Management remains optimistic about growth momentum continuing into FY27, supported by pipeline visibility and deeper customer relationships.
NEW RISK
Integration risk from multiple acquisitions
Management is simultaneously integrating JHawk and Bliss, which could strain resources and execution if not managed carefully.
NEW RISK
Customer conflict from pharma vertical integration
An analyst raised concern that Anupam's move into finished dosage forms could conflict with existing CDMO customers. Management downplayed the risk, citing market size and selectivity.
NEW RISK
Bliss GVS Pharma's historical underperformance
Bliss has low capacity utilization (30%) and has not engaged with investors recently. Turnaround may take longer than expected.
NEW RISK
Debt increase from acquisitions
The Bliss acquisition will add ~₹300 crore debt via NCDs, increasing consolidated gross debt to ~₹1,800 crore. While manageable, higher leverage could impact credit metrics.
RISK GONE
Integration risk from J-Hawk acquisition
The acquisition of J-Hawk Pine Chemicals involves integration of a US-based entity, which may pose operational and cultural challenges.
RISK GONE
Agro demand recovery sustainability
While agro demand has shown recovery, sustainability depends on global channel inventory normalization and end-market conditions.
RISK GONE
Working capital intensity remains high
Working capital days at ~250 are elevated; any delay in improvement could pressure cash flows.
Fast read
Guidance and risk preview
Management expects standalone business to grow at 20-30% annually, driven by order book conversion and new molecule commercialization.
Management is simultaneously integrating JHawk and Bliss, which could strain resources and execution if not managed carefully.
View Risks →